URGN: Strong demand for Zusduri and advancing pipeline programs signal robust growth prospects
The discussion highlighted strong early demand for Zusduri, with significant room for physician adoption and growth, especially in community settings. Key pipeline milestones include UGN-103's upcoming data and approval, UGN-104's trial progress, and the initiation of UGN-501 studies, supporting lo…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.